Metal compounds have been used as antibacterial agents for centuries. The in-vitro activity of two metal containing complexes, one gold, the other osmium, was investigated using a panel of clinically isolated bacteria and Candida aJbicans. Twenty strains of each organism were used and MIC and MBC values determined using the agar plate dilution method. Protein binding effects on the activity of the compounds were also investigated using media supplemented with 5% human blood. In-vivo activity of the two compounds was subsequently determined in a hairless-obese mouse skin-surface activity model. Both compounds were highly active against the Gram-positive organisms and Candida albicans in vitro. The gold compound had some Gram-negative activity but the osmium complex was inactive against these organisms. Both were extensively protein bound. In the in-vivo experiment the gold compound achieved a 2-3 log reduction for all the test organisms and was at least as good as or superior to mupirocin in its eradication rate. The osmium compound was inactive.
Introduction
The antibacterial properties of metals have been recognised for centuries and have represented some of the most fundamental breakthroughs in medicinal history. Probably the first laboratory antibacterial experiments involved a metal compound, namely Koch's investigation into the activity of mercuric chloride on anthrax spores (Koch, 1890) ; and the introduction of the metalloid organoarsenical compound Salvarsan™ in 1912 for the treatment of syphilis is considered to be the first example of the use of a synthetic therapeutic agent.
The medicinal use of mercury can be traced back to at least the 10th century. Inorganic mercury compounds were used to treat skin diseases and syphilis (O'Shea, 1990) , and more recently organo-mercurial compounds have been used as antiseptics and biocides. Organic salts of copper and zinc also have mild antiseptic properties although more commonly they are used in the treatment of fungal infections such as athlete's foot. Other metals reported to exert a toxic effect on bacteria include the precious metals platinum and silver (Ferguson, Murray & Lancy, 1979; Thurman & Gerba, 1989) . The original observations that platinum-ammine complexes had antibacterial properties (Rosenberg et al., 1967) led to the discovery of their anti-tumour properties and the development of the highly successful platinum anti-cancer drugs cisplatin and carboplatin. The antimicrobial properties of silver have been exploited for centuries; silver lined containers were once used to store water and the introduction of topical silver nitrate for the treatment of infantile blindness in 1884 was seen as a significant medical breakthrough.
The concept of gold as an antibacterial therapy can be traced back to the 8th century (Sadler, 1976) . The first scientific examination of gold compounds as antibacterial agents came in 1890 with the discovery that gold cyanide was inhibitory to 'tubercle bacilli' in vitro but not in vivo (Koch, 1890) . Indeed, the introduction of gold compounds for the treatment of rheumatoid arthritis was based on their antibacterial activity as it was assumed that bacteria were responsible for this condition (Lande, 1927) . Recently, complexes of gold have been reported to have a wide range of antimicrobial activities (Elsome et al., 1991) . We report here on the in-vitro and in-vivo activities of two compounds containing transition elements, namely a gold(I) complex JM 1796, and an osmium(VI) compound, JM 1397. 
Materials and methods

Test compounds
Media
All media were supplied by Unipath, Basingstoke, Hants, UK.
Microbial strains and culture techniques
Strains of methicillin-resistant Staphylococcus aureus (MRSA) were taken from countries around the world (Maple, Hamilton-Miller & Brumfitt, 1989 The organisms used for the in-vivo studies at the Institute of Dermatology were also evaluated in vitro.
Microbiological methods
Minimum inhibitory concentration (MIC) values were determined by the agar plate dilution technique (Woods & Washington, 1995) , using an inoculum of lO'cfu applied with a multi-point inoculating device (Denley, Billinghurst, UK). Plates were read after 18 h incubation at 37°C. Minimum bactericidal concentration (MBC) values were determined by replication from MIC plates using velvet pads, onto fresh medium; the end-point was taken as 99.9% killing. Results were summarised by calculating MIC»/9o and MBC X/K values by cumulation and interpolation (Hamilton-Miller, 1991) . Control plates, incorporating solvent only, were included to ensure that this was not having an inhibitory effect.
Protein binding was calculated from determinations of MICJO for 20 strains of S. aureus in both the presence and absence of 5% human blood, thus: % protein binding = 100 x (MICo with blood-MIC50 without blood)/MIC» with blood.
Microbial strains and culture techniques for in-vivo studies
Antibiotic-sensitive laboratory strains of S. aureus, P. mirabilis, P. aeruginosa, E. faecalis and C. albicans were used. These were routinely grown on Cystine Lactose Electrolyte Deficient (CLED) medium (S. aureus, P. mirabilis and P. aeruginosa), Blood Agar Base supplemented with 7% horse blood (BAB) (5. aureus), MacConkey Agar No. 2 (E. faecalis) or Sabouraud Dextrose Agar (C. albicans).
Animal model
Pairs of hairless-obese mice, bred in the Institute of Dermatology, were inoculated on intact skin of the back over an area of 2 x 2 cm with cultures varying in density from 10* to 10* cfu/mL using a cotton tipped swab. Inocula were prepared by scraping overnight growth (2 day growth for C. albicans) from an agar plate and suspending it in Nutrient Broth. Cetomacrogol cream (BP) with or without test compound (1% w/w) was then applied to the same area at a rate of 0.01 g/cm 2 . In one instance commercial 2% mupirocin cream (Bactroban, SmithKline Beecham) was used. The area was then covered with a square of sterile plastic held in place by Steridrape (3M). Mice were allowed food and water without restraint.
After 24 h the dressing was removed and the inoculated area sampled with a sterile cotton swab moistened in Nutrient Broth. The swab was shaken vigorously in 2 mL Nutrient Broth for 1 min using a vortex mixer. The suspension was diluted in serial ten-fold steps, quantitatively inoculated onto agar and incubated at 37°C. After either 24 h (bacteria) or 48 h (C. albicans) the plates were examined and colonies counted at the most suitable dilution.
To ensure that neither compound exerted an inhibitory effect on the growth of recovered cells, a comparative count with and without a suitable inactivator was performed. Using 5. aureus, BAB containing 0.5% dithiothreitol was used in parallel to plain BAB for JM 1796 and results from each system compared. A comparison of A. M. Eteome et al. cell recovery for CLED and BAB was used for JM 1397, since this compound is inactivated in the presence of serum (see 'protein binding studies').
Results
In-vitro antimicrobial activity
The solvent had no antimicrobial effect at the concentrations employed. JM 1397 was highly active against MRSA, enterococci and C. albicans (Table I) , but did not inhibit the growth of the Gram-negative species tested. It is of interest that the compound was cidal not only against staphylococci and C. albicans, but also for enterococci, at 4 x the respective MIC value. JM 1796 inhibited MRSA, enterococci and P. mirabilis at low concentrations (MIC <, 4 mg/L), but was less active against P. aeruginosa and C. albicans. MBC values were generally close to MIC values, except for the enterococci (Table II) .
The MIC and MBC values obtained for the strains used for the in-vivo studies were consistent with these findings. JM 1397 was highly active against both the Gram-positive organisms and the C. albicans and inactive against the two Gram-negative bacteria. JM 1796 had the same spectrum of activity for the laboratory strains as measured for the clinical isolates (Table III) . 
Protein binding studies
Results of experiments using 5% whole human blood showed that JM 1397 and JM 1796 were extensively bound to protein at 97% and 91% respectively. 
ln-vivo antimicrobial activity
Viable counts of recovered organisms from three experiments are shown in Table IV . Colonies recovered from paired mice are here averaged. Initial inoculation counts (i.e. time 0 h) are not given as it is difficult to determine what proportion of the culture used to inoculate the skin (by rolling a swab dipped in culture over the skin surface) remains on the skin after inoculation. However, the similarity of replicate counts of recovered organisms at 24 h gives a good indication that the initial inoculum was standard. There was no evident difference in counts with or without inactivator. JM 1796 was the most efficacious compound in all instances, reducing numbers of all the test organisms with respect to the controls. JM 1397 was inactive under the conditions of this test.
Discussion
Gram-negative organisms have an outer membrane, which provides an effective control over the uptake of toxic substances, and as a consequence are generally more resistant to antibacterial agents (Vaara, 1992) . This was certainly the case for the two metal complexes investigated here. The Gram-positive organisms used were more sensitive to both compounds tested whilst the Gram-negative bacteria were more resistant, particularly to the osmium(VI) complex, JM 1397. This specificity of activity suggests that the sensitivity of the test organisms to the test compounds is associated with the different cell wall structures characterised by the Gram stain. Previous studies looking at the interactions of gold(I) compounds with biological systems suggest that the major mode of action involves the highly specific coordination of gold(I) to thiol groups on proteins, and particularly with L-cysteine, although other groups are thought to be involved (Smith Brown & Cappell, 1985) . Studies looking at microbially-deposited gold have shown that positively charged residues such as RNH 3 + , R^N + and coordinating ligands such as RSH and R 2 S are important for gold binding (Watkins et al., 1987) . The reduced activity of the gold(I) compound against the Gram-negative organisms may be due to a lack of availability of such groups to the complex.
The potent activity that both of the compounds demonstrated against Gram-positive bacteria was of particular interest. The incidence of multiply antibiotic-resistant Gram-positive cocci is a major and growing clinical concern, demanding new strategies in antimicrobial chemotherapy.
The therapeutic efficacy of the drugs currently available for the treatment of Gram-positive organisms is limited in the treatment of the 'problem Gram-positive cocci'. Many are inactive against MRSA, MARSA and/or enterococci; there is the emergence of resistant strains; intense monitoring is required during treatment; many are unproven in severe infections; and they are expensive. Vancomycin is the drug of choice in MRSA and MARSA infections. However, administration must be by iv infusion and resistance to vancomycin and teicoplanin has been widely reported, particularly amongst enterococci (Leclerq et al., 1988; Greenwood, 1989; Johnson et al., 1990) . The activity of both compounds against MRSA and enterococci in vitro indicate the potential for metal coordination complexes to overcome the limitations experienced with the antibiotics currently available to treat these organisms.
In general, the in-vivo results of all the test organisms showed an approximately 2-3 log decrease in count for JM 1796 but a failure to decrease with JM 1397. The log cell kill for JM 1796 was similar to that of mupirocin against S. aureus and superior to mupirocin for the other organisms (W. C. Noble, personal communication) . JM 1397 showed no activity against any of the test organisms in vivo despite obvious activity in vitro. The extent to which this compound is protein bound and hence inactivated, in the presence of serum, is the most probable explanation for this observation.
The hairless-obese mouse has been shown previously to be a valuable model for the study of gene transfer between staphylococci (Naidoo & Noble, 1978 Noble, Virani & Cree, 1992) and in this to parallel the results obtained with human skin. Antibiotic or bacteriocin production and the resultant interaction between organisms has also been studied using this model (Noble & Willie, 1980; Noble, 1988) .
In conclusion, the data presented here both in vitro and in vivo has identified JM 1796 [Au(SCN)(PMe 3 )] as a metal containing complex of potential therapeutic benefit, particularly for the topical treatment of multiply antibiotic resistant Gram-positive bacteria.
